Brain chemistry probe: experimental drug SAGE-718 tested in healthy volunteers

NCT ID NCT03770780

Completed Knowledge-focused Sponsor: Supernus Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 1 study tested an experimental drug called SAGE-718 in 19 healthy volunteers. Participants received either SAGE-718 or a placebo, along with ketamine, to see how the drug affects brain chemicals like glutamate. The goal was to check safety and measure brain activity using MRI scans, not to treat any disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SAGE-718
What this could lead to: If successful, this could help researchers understand how SAGE-718 affects brain chemistry, potentially guiding future studies for conditions like depression or cognitive disorders.
What could go wrong: This is a very early Phase 1 trial in only 19 healthy people, not patients. It measures brain signals, not actual treatment effects, so results may not lead to any therapy.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY VOLUNTEER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEALTHY VOLUNTEER

Contacts and locations

Locations

Sage Investigational Site

Long Beach, California, 90806, United States
Sage Investigational Site

Berlin, New Jersey, 08009, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.